Heart Failure Clinical Trial
LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific’s Investigational ICM System.
Summary
The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.
Full Description
The primary objective of this study is to collect physiological measurement data and heart failure (HF) event data that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems. This study will not have pre-defined statistical endpoints. To support the primary objective, diagnostic sensor data will be compared to reference clinical testing data and heart failure decompensation events.
Eligibility Criteria
Key Inclusion Criteria:
Patient is currently in NYHA Class II or III.
For patients with LVEF >40% measured on most recent available echocardiography within the previous 12 months:
ONE (1) of the following echocardiography findings: LA width (diameter) >3.8 cm, LA length >5.0 cm, LA area >20 cm2, LA volume >55 ml, LA volume index >29 ml/m2, LVH defined by septal thickness or posterior wall thickness of >1.1 cm AND
ONE (1) of the following: Elevated BNP/NT-proBNP as defined by: BNP >100 pg/ml or NT-proBNP >300 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP >300 pg/ml or NT-proBNP >900 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months
For patients with LVEF <40% (for MI patients, measured no less than 30 days post-MI) on most recent available echocardiography within the previous 12 months:
ONE (1) of the following: Elevated BNP/NT-proBNP as defined by BNP >150 pg/ml or NT-proBNP >600 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP >450 pg/ml or NT-proBNP >1800 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months
Patient is willing to be monitored in LATITUDE Clarity and use the ICM patient mobile app.
Patient is of legal age to give informed consent and is willing to participate in the trial.
Key Exclusion Criteria:
Patient is currently implanted with any other active electronic medical device.
Patient has undergone a heart transplant.
Patient is currently enrolled in another investigational study (excluding registries) without prior written approval from Boston Scientific.
Patient is known to be pregnant at the time of enrollment or plans to become pregnant during study participation.
Patient is diagnosed with amyloidosis or hypertrophic cardiomyopathy.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 61 Locations for this study
Birmingham Alabama, 35243, United States
Mobile Alabama, 36608, United States
Jonesboro Arkansas, 72401, United States
Concord California, 94520, United States
La Jolla California, 92037, United States
Loma Linda California, 92357, United States
Los Angeles California, 90027, United States
Orange California, 92868, United States
San Diego California, 92123, United States
Ventura California, 55109, United States
Gainesville Florida, 32605, United States
Gainesville Florida, 32608, United States
Jacksonville Florida, 32216, United States
Lady Lake Florida, 32159, United States
Naples Florida, 34119, United States
Orlando Florida, 32806, United States
Sarasota Florida, 34239, United States
Augusta Georgia, 30901, United States
Augusta Georgia, 30912, United States
Gainesville Georgia, 30342, United States
Gainesville Georgia, 30501, United States
Boise Idaho, 83712, United States
Chicago Illinois, 60611, United States
Downers Grove Illinois, 60515, United States
Indianapolis Indiana, 46237, United States
Indianapolis Indiana, 46250, United States
Iowa City Iowa, 52242, United States
Kansas City Kansas, 66160, United States
Lexington Kentucky, 40503, United States
New Orleans Louisiana, 70112, United States
Boston Massachusetts, 02115, United States
Maplewood Minnesota, 55109, United States
Minneapolis Minnesota, 55417, United States
Jackson Mississippi, 39219, United States
Tupelo Mississippi, 38801, United States
Kansas City Missouri, 64111, United States
Saint Louis Missouri, 63110, United States
Newark New Jersey, 07103, United States
Sewell New Jersey, 08080, United States
Albany New York, 12211, United States
Brooklyn New York, 11215, United States
New York New York, 10032, United States
New York New York, 11355, United States
Charlotte North Carolina, 28204, United States
Greensboro North Carolina, 27408, United States
Raleigh North Carolina, 27610, United States
Winston-Salem North Carolina, 27157, United States
Springfield Oregon, 97477, United States
Allentown Pennsylvania, 18103, United States
Hershey Pennsylvania, 17033, United States
Philadelphia Pennsylvania, 19107, United States
Pittsburgh Pennsylvania, 15213, United States
York Pennsylvania, 17403, United States
Charleston South Carolina, 29401, United States
Nashville Tennessee, 37205, United States
Nashville Tennessee, 37232, United States
Powell Tennessee, 37849, United States
Galveston Texas, 77555, United States
Pasadena Texas, 77505, United States
Seattle Washington, 98108, United States
Vancouver Washington, 98664, United States
Huntington West Virginia, 25701, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.